CMAB vs IMAB in metastatic prostate cancer
Study identifier:D6876L00010
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
Longitudinal, randomized, open and prospective clinical trial to evaluate the efficacy of continuous vs intermittent maximum androgen blockade (CMAB vs IMAB) with goserelin-bicalutamide combination in the treatment of hormonal naïve with metastatic prostate cancer
Medical condition
Metastatic Prostate Cancer
Phase
Phase 4
Healthy volunteers
No
Study drug
Goserelin, Bicalutamide
Sex
Male
Actual Enrollment
15
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Aug 2004
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Aug 2007 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
AstraZeneca Mexico Medical Director
AstraZeneca
